Success Metrics

Clinical Success Rate
92.5%

Based on 136 completed trials

Completion Rate
93%(136/147)
Active Trials
6(3%)
Results Posted
43%(59 trials)
Terminated
11(6%)

Phase Distribution

Ph phase_2
23
12%
Ph early_phase_1
1
1%
Ph phase_3
45
24%
Ph phase_4
61
33%
Ph not_applicable
24
13%
Ph phase_1
27
14%

Phase Distribution

28

Early Stage

23

Mid Stage

106

Late Stage

Phase Distribution181 total trials
Early Phase 1First-in-human
1(0.6%)
Phase 1Safety & dosage
27(14.9%)
Phase 2Efficacy & side effects
23(12.7%)
Phase 3Large-scale testing
45(24.9%)
Phase 4Post-market surveillance
61(33.7%)
N/ANon-phased studies
24(13.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.2%

136 of 156 finished

Non-Completion Rate

12.8%

20 ended early

Currently Active

6

trials recruiting

Total Trials

187

all time

Status Distribution
Active(10)
Completed(136)
Terminated(20)
Other(21)

Detailed Status

Completed136
unknown21
Terminated11
Withdrawn9
Recruiting5
Not yet recruiting4

Development Timeline

Analytics

Development Status

Total Trials
187
Active
6
Success Rate
92.5%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (0.6%)
Phase 127 (14.9%)
Phase 223 (12.7%)
Phase 345 (24.9%)
Phase 461 (33.7%)
N/A24 (13.3%)

Trials by Status

active_not_recruiting11%
completed13673%
withdrawn95%
unknown2111%
not_yet_recruiting42%
terminated116%
recruiting53%

Recent Activity

Clinical Trials (187)

Showing 20 of 187 trialsScroll for more
NCT07564726Phase 3

Efficacy and Safety of Ezetimibe/Rosuvastatin and Amlodipine Patients With High Blood Pressure and High Cholesterol

Completed
NCT04840342Phase 4

MR Antagonist and LSD1

Active Not Recruiting
NCT01120327Phase 4

A Pilot Study Exploring Efficacy and Safety of Amlodipine in the Stented Angina Patients

Completed
NCT05312892Phase 1

Sympathetic Mechanisms in Obesity-Crossover Design

Recruiting
NCT07075965Phase 1

Calcium Channel Blocker in Myotonic Dystrophy Type 1

Not Yet Recruiting
NCT07241338Phase 4

Sacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity

Not Yet Recruiting
NCT05103332Phase 2

Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)

Completed
NCT02847338Phase 4

Comparison of Optimal Hypertension Regimens

Completed
NCT06150560Phase 3

A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial)

Recruiting
NCT02373163Phase 4

INTERVENCION Trial

Completed
NCT06942377Phase 2

Calcium Channel Blocker Amlodipine for Endometrial Cancer Therapy

Not Yet Recruiting
NCT02904291

Bariatric Surgery and Pharmacokinetics of Amlodipine

Recruiting
NCT04179019Phase 2

Calcium Channel Blockade in Primary Aldosteronism

Completed
NCT05513937Phase 4

Effectiveness and Safety of Combination of Nebivolol and Amlodipine in Hypertensive Patients Versus Each Monotherapy

Completed
NCT06713785Phase 4

Personalised Electronic Record Supported Optimisation of Amlodipine for Patients With Hypertension

Withdrawn
NCT06424834Phase 2

Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries

Recruiting
NCT04790279Phase 4

Amlodipine Versus Nifedipine ER for the Management of Postpartum Hypertension

Completed
NCT05279807Phase 4

Effectiveness and Safety of Combination of Amlodipine and Zofenopril in Hypertensive Patients Versus Each Monotherapy

Completed
NCT05917275Phase 4

Multi-Omics to Predict the Blood Pressure Response to Antihypertensives

Recruiting
NCT00006294

Genetics of Hypertension Associated Treatments (GenHAT)

Completed

Drug Details

Intervention Type
DRUG
Total Trials
187